Senolytics Reverse Brain Aging by Blocking Cholesterol Buildup in Astrocytes
Dasatinib and quercetin improve memory in aging mice by suppressing a key cholesterol pathway in brain support cells, revealing a new longevity mechanism.
Summary
Researchers discovered that the senolytic drug combination dasatinib and quercetin (D+Q) improves cognitive function in aging mice by targeting cholesterol biosynthesis in astrocytes — the brain's support cells. Using a D-galactose accelerated-aging mouse model, the team found that D+Q reduced cellular senescence and significantly downregulated cholesterol production in the hippocampus. Multi-omics analysis pinpointed astrocytes as the key site of action. When cholesterol synthesis was artificially reactivated — either pharmacologically or by overexpressing the enzyme Hsd17b7 — the cognitive and anti-senescence benefits of D+Q were reversed, confirming the causal role of this pathway. The findings reframe senolytics as brain lipid metabolism modulators, opening a new therapeutic direction for age-related cognitive decline.
Detailed Summary
Cognitive decline during aging is closely linked to the accumulation of senescent cells in the brain. Senolytics — compounds that selectively eliminate these dysfunctional cells — have shown promise for preserving cognition, but the precise molecular mechanisms have remained unclear. This study provides important mechanistic insight by identifying astrocytic cholesterol biosynthesis as a central target of senolytic action.
The research team used a D-galactose-induced accelerated aging mouse model, a well-established system for studying age-related brain changes, and treated animals with dasatinib and quercetin (D+Q), the most clinically advanced senolytic combination. Treated mice showed significant improvements in cognitive performance alongside reductions in markers of cellular senescence throughout the brain.
A multi-omics approach — integrating transcriptomic and metabolomic data — revealed that D+Q treatment specifically downregulated cholesterol biosynthesis pathways in the hippocampus. Critically, this effect was localized to astrocytes, where senolytics reduced intracellular lipid accumulation and subsequent neuroinflammation, two hallmarks of brain aging.
To establish causality, the researchers either pharmacologically activated cholesterol synthesis or genetically overexpressed Hsd17b7, a rate-limiting enzyme in the cholesterol synthesis pathway, in astrocytes in vitro. Both interventions reversed the anti-senescence effects of D+Q, directly linking cholesterol pathway suppression to the therapeutic benefit.
These findings reposition senolytics not merely as cell-clearing agents but as modulators of brain lipid metabolism. The identification of astrocytic cholesterol accumulation as a driver of cognitive aging suggests that targeting this pathway — through senolytics or future Hsd17b7 inhibitors — could be a promising strategy for treating age-related dementia. Limitations include the use of an accelerated aging model rather than naturally aged animals, and all mechanistic experiments were conducted in vitro.
Key Findings
- Dasatinib and quercetin improved cognitive performance and reduced senescence in D-galactose-aged mice.
- Multi-omics analysis identified hippocampal cholesterol biosynthesis as the primary pathway downregulated by senolytics.
- Senolytics specifically reduced lipid accumulation and neuroinflammation within astrocytes, not neurons.
- Overexpressing Hsd17b7 in astrocytes reversed senolytic benefits, confirming a causal cholesterol-senescence link.
- Findings reframe senolytics as brain lipid metabolism modulators, not just senescent cell eliminators.
Methodology
Researchers used a D-galactose-induced accelerated aging mouse model treated with dasatinib and quercetin. A multi-omics approach (transcriptomics and metabolomics) was applied to identify affected pathways. Causal validation was performed in vitro through pharmacological activation and genetic overexpression of Hsd17b7 in astrocytes.
Study Limitations
The D-galactose model mimics accelerated aging but may not fully replicate natural brain aging processes seen in humans or aged rodents. Mechanistic causal experiments were performed in vitro, requiring in vivo confirmation. The study does not address long-term safety or efficacy of repeated senolytic dosing on brain lipid homeostasis.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: